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Purpose: To evaluate the outcomes of the metallic Resonance® ureteral
stent and clarify the risk factors that lead to stent failure. In the present
study, we present 5 years of our experiences with the use of a Resonance
stent for malignant and benign ureteral obstruction.
Materials and Methods: We retrospectively identiﬁed and analyzed the
records of all patients in whom Resonance® Metallic Ureteral Stent was
placed between early 2009 and late 2014 in our hospital. We performed a
descriptive analysis of key outcomes, including the failure and stenting
duration, deﬁned as the time from initial stent placement to last stent
failure or patient death.
Results: A total of 52 metallic stents were placed in 36 patients, including
44 (84.6%) with malignant and 8 (15.4%) with a benign etiology. Maximum
follow-up was 58 months (mean 14.7, median 8.5, IQR 14.9). Stent failure
occurred in 10 patients (19.2%). The re-occlusion rate was signiﬁcantly
higher in the subgroup with urinary bladder invasion malignancy during
Resonance stent insertion (p ¼ 0.035). Patients who had had previous
radiation therapy had a lower patency rate in comparison with non-radi-
ation patients (p ¼ 0.001), especially in patients with Resonance stent
placement more than one year (p ¼ 0.018). And the 50% patency rate with
52 stents was 10 months.
Conclusion: The Resonance metallic stent could be safely applied for those
malignant or benign ureteral obstructions. For malignant ureteral
obstruction, previous radiation therapy is a risk factor for stent failure,
especially for those with long-term stent placement. We also suggested
revision of Resonance metallic stent every one year to keep stent patency
and prevent stent complications.
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Purpose: Evaluate the difference in the subjective in pain of using different
probes for transrectal ultrasound of prostate Material and Method: From
July 2014 to December 2014, patients undergoing transrectal ultrasound of
prostate (TRUS) were randomly divided into two groups, using two
different probes. A visual analogue (VAS) was used to evaluate the sub-
jective perception of pain in these patients.
Results: A signiﬁcant difference was found in VAS between the two
groups. The patient felt less pain during TRUS examination when using
micro convex transducer. Besides, patients with external hemorrhoid,
longer prostate sagittal length, and artifacts caused by stool were all found
to be associated with more pain. The usage of micro convex transducer can
help to reduce the pain for the patients with external hemorrhoids,a Dr. Hsu and Wang contribute equally to this manuscript and serve as co-ﬁrst
authors.whereas there was no difference of pain perception when the patient has
previous rectal surgery or artifacts caused by stool.
Conclusion: We identiﬁed the factors of pain associated with TRUS. Micro
convex transducer caused less pain associated TRUS than Bi-planed linear
transducer.
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Purpose: This study was done to compare the length and form of anes-
thesia that is suitable for patients undertaking rigid cystoscopy procedure
under local anesthesia.
Materials and Methods: From September 2014 to March 2015, a single
Fellow surgeon performed removal of double-J catheter with rigid
cystoscopy on 34 patients whom were randomized into two groups. One
group received intra-uretheral injection of 4% xylocaine (2 minutes) with
addition of 2% xylocaine jelly (1 minute) and another group with single
dose of intra-uretheral injection of 4% xylocaine (3 minutes). Both groups
received same amount of total anesthesia time (3 minutes). Several factors
were used to analyze the effectiveness of local anesthesia (difference of pre
and post-operative blood pressure and heart rate, VAS score, and patient's
own description). Factors that may inﬂuence the effectiveness of local
anesthesia were also recorded (form of anesthesia, length of anesthesia,
BMI, depression angle of bladder neck, age, and any cystoscopy ﬁnding).
Bladder neck depression anglewere estimated by recording the cystoscopy
insertion length and the actual depression when entering the bladder.
Trigonometry formula for angle using inverse sin was used to estimate the
depression angle.
Results: Thirty-four patients were included in this initial study. Initial data
showed that decrease anesthesia time with liquid xylocaine, BMI, age and
bladder neck depression angle of more than 30 degrees is associated with
increase pain (increase in VAS and heart rate). All patients still experienced
soreness even with increase length of anesthesia.
Conclusion: Studies have shown that a minimum of 5 minutes will be
needed for rigid cystoscopy examination. Due to our current environment
which demands maximizing efﬁciency without compromising patients'
priorities, the use of adequate form and length of anesthesia should be a
concern. Our initial data showed us that a liquid anesthesiawith either 2 or
4% xylocaine with a minimum of 3 minutes is sufﬁcient in performing rigid
cystoscopy examination under local anesthesia.
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Purpose: Ketamine associated cystitis presented with severe dysuria,
frequency, urgency, lower abdominal pain and gross hematuria. Due to its
pathologic damage, the ﬁlling bladder volume is decreased. In our hospital
we performed bladder augmentation in 4 cases of ketamine associated
cystitis from 2004 to 2013.
Materials and Methods: All 4 patients was ketamine abuser and diag-
nosed by clinical symptoms and cystoscopic examination of ulceration
with severe diffuse hemorrhage and low bladder capacity from 2004 to
2013. They all received bladder augmentation. The data on demographics,
clinical characteristics, and patient outcomes were collected. All the data
were yielded retrospectively.
Results: Total of 4 patients with ketamine associated cystitis received
bladder augmentation at E-Da tertiary medical center from 2004 to 2013.
Male patients were predominant (male : female ¼ 3:1). The average age at
operation is 29.75. ( ranged 28-32 ) The average ketamine abuse time is
9.25 years. ( ranged 8-11 ) After bladder augmentation of surgery, the post-
Abstracts / Urological Science 26 (2015) S1eS25S12voiding residual urinary amount increased and it improved capacity of
bladder that more than 200ml. The patients are satisﬁed with the outcome
of bladder augmentation and it improved the quality of life. Few times of
urinary tract infection are encountered during follow up in 2 patients. One
patient suffered from recurrent vesical stone without sepsis.
Conclusion: We shared our experience for refractory bladder pain due to
ketamine associated cystitis. The outcome of treatment depends on the
severity of the disease process. Although small number cases, bladder
augmentation may be needed in such patients. It improves bladder ca-
pacity and quality of life of the patients.Podium-7
Oncology
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Purpose:Aim: Reliable biomarkers are in urgent need for diagnosis, outcome
prediction or treatment effect monitoring for upper tract urothelial carci-
nomas (UTUC). Although up-regulation of cyclooxygenase 2 (COX-2) are
found in stroma and tumor cells in more than half of the UTUC patients
investigated, the genomic contribution ofCOX-2 toUTUC is never studied. The
study was to evaluate the association of six polymorphic genotypes of COX-2
with UTUCwithin a Taiwanese population. Materials andMethods: A total of
218 UTUC patients and 580 healthy controls were genotyped for six COX-2
polymorphisms, A-1195G,G-765C, T+8473C, intron 1, intron5, and intron6, of
their association with UTUC risk. Results: The distribution of genotypes of
COX-2G-765Cand intron5were signiﬁcantly different betweenUTUCpatient
and control groups (p ¼ 0.0001 and 0.0016, respectively), while others were
not (p>0.05). The haplotype analysis showed that compared with GG/TT
haplotype of COX-2 G-765C/intron 5, people carrying GG/AT variants have a
signiﬁcant increased risk of UTUC (odds ratio, OR ¼ 4.83, 95% conﬁdence in-
terval, 95%CI ¼ 1.79-13.06) while people carrying CG/TT variants have a
decreased risk (OR ¼ 0.26, 95%CI ¼ 0.14-0.49). Conclusion: Our results sug-
gested that individual and combinedCOX-2G-765C/intron 5 genotypes play a
role in controlling the COX-2 expression and UTUC development.
Materials and Methods: Sample collection. A total of 218 patients with
UTUC were recruited at China Medical University and Kaohsiung Medical
University medical centers, all of whom were diagnosed by pathologic
examination of specimens obtained by biopsy or surgical resection. The
clinical and histopathologic informationwere collected from patient charts
and pathologic reports. The information was reviewed, and the data were
entered into the database. The tumor stage was assigned according to the
TNM staging system (21), and the pathologic grade was determined ac-
cording to the World Health Organization criteria (22). Five hundreds and
eighty healthy individuals, who had been matched with the patients with
age, admitted to the same hospital for health checkup and who had no
previous diagnosis of urologic neoplastic disease or othermalignancywere
enrolled as controls. All the subjects enrolled were provided an informed
consent and Human Research Committees have approved this study.
Genotyping conditions. The total genomic DNA of each subject was extracted
from the leucocytes of peripheral blood and stored as previously published
(23-25). The polymerase chain reaction (PCR) cycling conditions were: one
cycle at 94

C for 5 min; 35 cycles of 94

C for 30 sec, 55

C for 30 sec, and 72

Ca These Authors contribute equally to this work.for 30 sec, and a ﬁnal extension at 72

C for 10 min. Pairs of PCR primer se-
quences and restriction enzyme for each DNA product of COX-2 genotyping
work are all listed in Table I. The PCR products were cut by proper restriction
enzymes and the reaction was incubated for 2 h at 37

C. Then, 10 ml of each
PCR product was loaded into a 3% agarose gel for electrophoresis.
Statistical analyses. Two hundreds and eighteen cases and ﬁve hundreds and
eighty controls were analyzed in the presented Tables. To ensure that the
controls used were representative of the general population and to exclude
thepossibility of genotypingerror, thedeviation of the genotype frequencies
of COX-2 single nucleotide polymorphism in the controls from those ex-
pected under the Hardy-Weinberg equilibrium was assessed using the
goodness-of-ﬁt test. Pearson's chi-square test or Fisher's exact test (when
the expected number in any cell was less than ﬁve)was used to compare the
distribution of the COX-2 genotypes between cases and controls. Cancer risk
associated with the genotypes was estimated as odds ratio (ORs) and 95%
conﬁdence intervals (CIs) using unconditional logistic regression. All sta-
tistical tests were performed using SPSS for Windows (version 14.0; SPSS
Inc., Chicago, IL, USA) on two-sided probabilities. The correlation between
categorical variables was calculated for statistical signiﬁcance using Pear-
son's chi-square test and the threshold for signiﬁcance was p<0.05.
Results: The frequency distributions of clinical characteristics for the
subjects (218 UTUC patients and 580 healthy controls) are shown in Table
II. Epidemiologically, there was no difference in the frequency distribution
between the gender (p ¼ 0.4256) or age (p ¼ 0.8518) since the population
was well matched (Table II). From the clinical and pathological viewpoints,
tumors distributed in renal pelvic, ureter and multiple sites were 38.5%,
34.9% and 26.6%, respectively. Among the patients, 60.6% were high grade,
and 77.1% were of stages lower than pT3 (Table II).
The frequencies of the genotypes for COX-2 A-1195G, G-765C, T+8473C,
intron 1, intron 5, and intron 6 among the UTUC patients and healthy
controls are summarized and analyzed in Table III. Among the six poly-
morphic genotypes investigated, two of them, G-765C (OR ¼ 0.32, 95%
CI ¼ 0.19-0.55, p ¼ 0.0001) and intron 5 (OR ¼ 3.91, 95%CI ¼ 1.71-8.95,
p¼ 0.0016), were found to be differentially distributed between UTUC case
and control groups (Table III). First, the frequencies of GG and CG geno-
types of COX-2 G-765C were 92.7 and 7.3% among UTUC cases, and 80.2
and 19.8% among healthy controls, respectively. Second, the frequencies of
TT and AT genotypes of COX-2 intron 5 were 93.6 and 6.4% among UTUC
cases, and 98.1 and 1.9% among healthy controls, respectively (Table III). As
for other polymorphic sites of COX-2, there was no difference in the dis-
tribution of genotypes among UTUC cases and controls (Table III). In the
next step, we have performed the allelic frequency analysis, and the fre-
quencies of the alleles for COX-2 A-1195G, G-765C, T+8473C, intron 1,
intron 5, and intron 6 among the UTUC cases and healthy controls are
summarized in Table IV. Consistent to the ﬁndings of Table III, G-765C and
intron 5 of COX-2were found to be associatedwith UTUC risk in Table IV. In
detail, higher frequencies of G allele in G-765C and A allele in intron 5 in
the UTUC case group than the control group, associating to higher risk of
UTUC (Table IV; p ¼ 0.0001 and 0.0017, respectively). Regarding to the
other four COX-2 polymorphic sites, no distribution of their allelic fre-
quencies was found to be signiﬁcantly different between the control and
UTUC case groups (Table IV). Considering the possible interactions be-
tween the two determinant COX-2 genotypes for UTUC susceptibility, the
haplotypic distributions of COX-2 G-765C and intron 5 were further
analyzed (Table V). We have set the most abundant genotypes for both G-
765C and intron 5 genotypes as wild-type for haplotypic combination.
Under this criteria, the “GG” genotype for COX-2G-765C and “TT” for COX-2
intron 5 were selected, resulting in setting GG/TT combinative genotype in
G-765C/intron 5 as the reference haplotype. Compared with the reference
haplotype of COX-2 G-765C/intron 5, the GG/AT group has a signiﬁcant
higher risk of UTUC (OR ¼ 4.83, 95%CI ¼ 1.79-13.06, p ¼ 0.0014) while CG/
TT has a lower risk (OR ¼ 0.26, 95%CI ¼ 0.14-0.49, p ¼ 0.0001) (Table V).
After adjusting for age and gender, the signiﬁcances became more obvious
for the GG/AT and CG/TT groups with their individual ORs altered to 4.86
and 0.32, remained statistically signiﬁcant (Table V). The combination of
CG/AT did not confer signiﬁcantly altered cancer risk compared to the
wild-type haplotype before or after adjusting for age and gender (Table V).
Conclusion: Urothelial carcinoma is the second most common cancer
which usually arises from the urothelium with transitional cell differen-
tiation, including that of the renal pelvis, ureter and bladder. In literature,
